Brokerages expect Aptevo Therapeutics Inc (NASDAQ:APVO) to post $6.87 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Aptevo Therapeutics’ earnings, with the lowest sales estimate coming in at $6.85 million and the highest estimate coming in at $6.89 million. Aptevo Therapeutics posted sales of $6.17 million in the same quarter last year, which suggests a positive year over year growth rate of 11.3%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full year sales of $24.75 million for the current year. For the next fiscal year, analysts forecast that the company will post sales of $29.10 million, with estimates ranging from $28.20 million to $30.00 million. Zacks’ sales averages are an average based on a survey of analysts that cover Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.07. The business had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $4.17 million. Aptevo Therapeutics had a negative return on equity of 45.53% and a net margin of 74.01%.

Several equities research analysts recently commented on the company. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Tuesday, August 14th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $11.00 price target on shares of Aptevo Therapeutics in a research note on Friday, August 10th.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in shares of Aptevo Therapeutics by 10.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,351,656 shares of the biotechnology company’s stock valued at $6,745,000 after buying an additional 131,804 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Aptevo Therapeutics by 53.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock valued at $5,736,000 after buying an additional 399,400 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Aptevo Therapeutics by 79.0% in the 2nd quarter. Acadian Asset Management LLC now owns 367,509 shares of the biotechnology company’s stock worth $1,833,000 after purchasing an additional 162,218 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Aptevo Therapeutics by 346.6% in the 1st quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock worth $832,000 after purchasing an additional 197,341 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Aptevo Therapeutics by 10.3% in the 1st quarter. Victory Capital Management Inc. now owns 215,110 shares of the biotechnology company’s stock worth $703,000 after purchasing an additional 20,000 shares during the last quarter. 33.08% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ APVO opened at $5.05 on Friday. The company has a market capitalization of $115.39 million, a P/E ratio of -3.30 and a beta of 0.68. Aptevo Therapeutics has a 52 week low of $2.13 and a 52 week high of $6.35. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.50.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Recommended Story: Outstanding Shares

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.